跳至主要内容
临床试验/JPRN-UMIN000030560
JPRN-UMIN000030560招募中未知

Comparison of tadalafil monotherapy and its combination with mirabegron for efficacy in the treatment of storage symptoms with benign prostatic hyperplasia - Comparison of tadalafil monotherapy and its combination with mirabegron for efficacy in the treatment of storage symptoms with benign prostatic hyperplasia

Division of Urology, Department of Surgery, Tottori University Faculty of Medicine0 个研究点目标入组 120 人开始时间: 2017年12月25日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
120

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
50years-old 至 ot applicable(—)
性别
Male

入选标准

  • 未提供

排除标准

  • Study exclusion criteria are post-void residual urine volume greater than 100 ml, acute urinary retention, neurogenic bladder dysfunction, severe bladder diverticulum or urethral stricture, urinary tract malignant disease, previous intrapelvic irradiation, renal or hepatic impairment, severe cardiac disease, or considered unsuitable for the trial by doctors.

研究者

发起方
Division of Urology, Department of Surgery, Tottori University Faculty of Medicine

相似试验

Comparison of tadalafil monotherapy and its... | 临床试验